> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbott Shifts $3.2 Billion Of Exact Sciences Price Into Intangibles, Adding About $100 Million Of Expense
- URL: https://www.bullished.co/abbott-shifts-3-2-billion-of-exact-sciences-price-into-intangibles-adding-about-100-c56654ee/
- Published: 2026-11-04T22:34:15.000Z
- Updated: 2026-11-04T22:34:15.000Z
- Description: The preliminary reallocation lifts Abbott's amortization schedule for 2026 through 2030, and the company says the final split could differ materially.
- Author: Matteo Parrino
- Tags: SEC Filings, ABT, Industry: Healthcare

[Abbott Laboratories](https://www.bullished.co/tag/abt/) moved [$3.2 billion](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026070154/abt-20260930.htm?ref=bullished.co) of its Exact Sciences purchase price out of goodwill and into intangible assets that must be written off over time, adding about $100 million of amortization expense in the third quarter, according to its 10-Q filed Wednesday. The shift raises the schedule of charges Abbott expects through 2030.

## How the purchase price was redrawn

Abbott, the health-care company behind Similac, FreeStyle Libre glucose monitors and heart devices, closed the roughly $20.6 billion Exact Sciences deal on March 23, 2026\. It funded the purchase mainly with $20.0 billion of new long-term debt.

Against the [prior quarter's filing](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026050134/abt-20260630.htm?ref=bullished.co), acquired intangibles rose from $12.8 billion to $16.0 billion, goodwill fell from $11.4 billion to $8.9 billion, and deferred income taxes recorded at acquisition went from $(2.0) billion to $(2.7) billion.

The 10-Q still calls the allocation preliminary. It says differences from the final allocation could be material, and that the split will be settled when the valuation of assets and liabilities is complete.

## A heavier amortization schedule

Abbott now estimates intangible amortization of about $3.0 billion in 2026 and $2.7 billion in 2027, followed by $2.1 billion in 2028, $2.1 billion in 2029 and $1.9 billion in 2030\. The prior filing's estimates for 2026 and 2027 were $2.6 billion and $2.3 billion.

Third-quarter amortization came to $841 million, against $420 million a year earlier. The 10-Q says higher amortization tied to Exact Sciences pulled gross margin down to 50.3% from 51.7%, and operating earnings fell to $1,358 million from $2,057 million.

The quarter also carried about $670 million of charges to settle the Gill case and necrotizing enterocolitis claims for roughly 2,000 additional infants, which Abbott says is not an admission of liability.

## Goodwill and a coming split

Goodwill assigned to Medical Devices stood at $17.2 billion at September 30, against $12.5 billion in Diagnostic Products, the segment that now holds Exact Sciences. Its cancer-diagnostics business contributed about $2.0 billion of sales in the first nine months.

Separately, Abbott said in October it intends to spin its Nutrition business into an independent public company by distributing shares to Abbott holders. Completion is targeted for late 2027 and hinges on the board's sign-off, regulators and an effective Form 10.

The next test is the final allocation, which Abbott says will be set once its valuation work is complete, with the 2026 amortization estimate at about $3.0 billion for now.

### Sources

- [10-Q Filing — Abbott Laboratories (ABT)](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026070154/abt-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Abbott Laboratories (ABT), Q2 FY2026 filed 2026-07-28 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026050134/abt-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, abt-2026q3xexhibitx991.htm) — Abbott Laboratories, filed 2026-10-21](https://www.sec.gov/Archives/edgar/data/0000001800/000162828026066601/abt-2026q3xexhibitx991.htm?ref=bullished.co) — SEC EDGAR
- [Abbott Laboratories (ABT) Posted Positive Trial Results For Two Heart Devices](https://nz.finance.yahoo.com/news/abbott-laboratories-abt-posted-positive-150925524.html?ref=bullished.co) — Yahoo Finance
- [Abbott Touts Favorable Outcomes In Cardiovascular Device Trials](https://finance.yahoo.com/healthcare/articles/abbott-touts-favorable-outcomes-cardiovascular-174830787.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Abbott Laboratories et al. Inter Partes Review](https://www.law360.com/ptab%5Fcases/67484b0da521f20255da96b2?ref=bullished.co) — law360.com
- [Abbott Laboratories (NYSE:ABT) : Cases :: Law360](https://www.law360.com/companies/abbott-laboratories/cases?ref=bullished.co) — law360.com
- [Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks (SP500:) (AVGO:NASDAQ)](https://seekingalpha.com/news/4661348-notable-analyst-calls-this-week-broadcom-moderna-and-abbott-among-top-picks?ref=bullished.co) — seekingalpha.com

### More on Abbott Laboratories

- [Abbott CEO Says Barron's 'Got It Totally Wrong' On Nutrition Spinoff, Calls It A Move From Strength](https://www.bullished.co/abbott-ceo-says-barrons-got-it-totally-wrong-on-nutrition-spinoff-calls-it-a-move-from-d9ea317d/)
- [Abbott Plans To Spin Off $8.5 Billion Nutrition Business By End Of 2027](https://www.bullished.co/abbott-plans-to-spin-off-8-5-billion-nutrition-business-by-end-of-2027-5afeb40c/)
- [Abbott's Third-Quarter Sales Rose 14.5%, But Reported Earnings Per Share Fell To $0.53 From $0.94](https://www.bullished.co/abbotts-third-quarter-sales-rose-14-5-but-reported-earnings-per-share-fell-to-0-53-from-0-1f51fad6/)

[All Abbott Laboratories (ABT) coverage →](https://www.bullished.co/tag/abt/)